TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Employees - 728,
CEO - Dr. Waleed H. Hassanein M.D.,
Sector - Healthcare,
Country - US,
Market Cap - 2.97B
Altman ZScore(max is 10): 4.46, Piotroski Score(max is 10): 7, Working Capital: $437303000, Total Assets: $804076000, Retained Earnings: $0, EBIT: 39412000, Total Liabilities: $575473000, Revenue: $441540000
- Current Price $88.24 - Analyst Target Price $103.38| Ticker | TMDX |
| Index | RUT |
| Curent Price | 88.24 |
| Change | 3.35% |
| Market Cap | 2.97B |
| Average Volume | 1.31M |
| Income | 35.46M |
| Sales | 441.54M |
| Book Value/Share | 6.80 |
| Cash/Share | 10.00 |
| Dividend Est | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Employees | 728 |
| Moving Avg 20days | 18.84% |
| Moving Avg 50days | 22.40% |
| Moving Avg 200days | -15.12% |
| Shares Outstanding | 33.62M |
| Earnings Date | Feb 27 AMC |
| Inst. Ownership | 110.65% |
| Price/Earnings | 87.35 |
| Forwad P/E | 39.24 |
| PE Growth | 2.03 |
| Price/Sales | 6.73 |
| Price/Book | 12.98 |
| Price/Cash | 8.82 |
| Price/FCF | - |
| Quick Ratio | 7.52 |
| Current Ratio | 8.30 |
| Debt/Equity | 2.27 |
| Return on Assets | 4.62% |
| Return on Equity | 19.39% |
| Return on Investment | 4.77% |
| Gross Margin | 59.29% |
| Ops Margin | 8.49% |
| Profit Margin | 8.03% |
| RSI | 70.61 |
| BETA(β) | 1.76 |
| From 52week Low | 60.44% |
| From 52week High | -50.25% |
| EPS | 1.01 |
| EPS next Year | 2.25 |
| EPS next Qtr | 0.26 |
| EPS this Year | 45.01% |
| EPS next 5 Year | 43.13% |
| EPS past 5 Year | - |
| Sales past 5 Year | 95.35% |
| EPS Y/Y | 239.32% |
| Sales Y/Y | 82.74% |
| EPS Q/Q | 65.14% |
| Sales Q/Q | 49.83% |
| Sales Surprise | 10.99% |
| EPS Surprise | 19.05% |
| ATR(14) | 5.19 |
| Perf Week | 15.54% |
| Perf Month | 25.47% |
| Perf Quarter | 52.09% |
| Perf Year | -5.43% |
| Perf YTD | 41.52% |
| Target Price | 103.38 |
AryaFin Engine© - An AI FinTech Venture - 2024-25 Disclaimer